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Summary
Purpose: To assess associations between serum transforming growth factor-beta (TGF-b1) and radiographic knee and hip osteoarthritis (rOA)
in African American (AA) and White men and women.
Methods: Baseline data from 330 participants in the Johnston County Osteoarthritis Project were used in the analysis. Radiographs were
scored with the KellgreneLawrence scale and rOA deﬁned as grade 2. Individual radiographic features (IRFs) were rated 0e3. TGF-b1
was measured using a sandwich enzyme-linked immunosorbent assay (ELISA). General linear models were used to estimate associations
between lnTGF-b1 and rOA presence, laterality or severity, and IRF presence and severity, adjusting for age, gender, race and body
mass index. Interactions by race and gender were considered signiﬁcant at P< 0.1.
Results: Mean lnTGF-b1 levels were higher among AAs compared to Whites, and among women compared to men (P< 0.009). Mean lnTGF-
b1 levels were higher in those with knee osteophytes (OST), but this association was not signiﬁcant after adjustment. There were no other
signiﬁcant differences in mean lnTGF-b1 levels by presence, laterality, or severity of knee or hip rOA or IRFs. No race or gender interactions
were identiﬁed, although a borderline signiﬁcant association between lnTGF-b1 and knee OST was seen among AAs (P< 0.06).
Conclusions: Although serum TGF-b1 varied by race and gender and several rOA variables, there were no independent signiﬁcant associa-
tions with presence, laterality, or severity of knee or hip rOA by KeL grade or IRFs, suggesting that serum TGF-b1 is unlikely to be useful as
a stand-alone biomarker in OA studies. A possible association between TGF-b1 and OST in AAs cannot be excluded.
ª 2008 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
Key words: Biomarkers, Transforming growth factor-beta (TGF-b1), Radiography.Introduction
Osteoarthritis (OA) is the most common type of arthritis, af-
fecting an estimated 27 million adults aged 25 years and
older1. Plain radiographs are the standard method for as-
sessing OA presence, severity and progression. These
can be scored either for individual radiographic features
(IRFs) such as osteophytes (OST), joint space narrowing
(JSN), subchondral sclerosis, and subchondral cysts, or
by using a global scale that accounts for these features,
such as the KellgreneLawrence (KeL) grade2. We have
recently identiﬁed differences by race in IRFs of OA at the1The ﬁndings and conclusions in this report are those of the au-
thors and do not necessarily represent the ofﬁcial position of the
Centers for Disease Control and Prevention.
*Address correspondence and reprint requests to: A. E. Nelson,
Thurston Arthritis Research Center, University of North Carolina
School of Medicine, 3300 Thurston Building, Campus Box #7280,
Chapel Hill, NC 27599-7280, USA. Tel: 1-919-966-4191;
Fax: 1-919-843-7231; E-mail: aenelson@unch.unc.edu
Received 13 August 2008; revision accepted 11 November 2008.
772knee and hip, including variations in JSN and increased
OST at these joint sites in African American (AA) individuals
compared to Whites3,4. However, plain radiographs have
several drawbacks in OA assessment, including insensitiv-
ity to change for short term follow-up and lack of tight asso-
ciation with patient outcomes such as pain and disability.
Biomarkers represent a potentially more sensitive way to
evaluate and follow OA patients for the purposes of clinical
research and therapeutic trials. Serum and urine bio-
markers provide a rapid and relatively non-invasive method
of repeated assessment over time, and may be more
responsive to therapeutic interventions than the longer-
term changes seen on radiographs5,6.
Transforming growth factor-beta (TGF-b) holds promise
as a potential serum biomarker of OA. The TGF-b family
consists of three closely related isoforms, (TGF-b1), -b2,
and -b3, with TGF-b1 being the most abundant and most of-
ten studied in relation to bone and OA7. TGF-b1 is a multi-
functional growth factor with widespread effects on multiple
tissues, including an important role in cartilage matrix
metabolism. Elevated TGF-b1 levels have been identiﬁed
Table I








White 190 15.80 (6.10e40.80) 2.78 (2.73e2.83) 0.009z
AA 140 18.35 (7.00e40.90) 2.88 (2.82e2.93)
Gender
Men 130 15.20 (6.10e37.00) 2.74 (2.69e2.80) 0.001z
Women 200 18.30 (6.20e40.90) 2.87 (2.82e2.92)
Knee rOA
Absent 152 16.35 (6.10e40.80) 2.79 (2.74e2.85) 0.185
Present 178 17.30 (6.20e40.90) 2.84 (2.79e2.89)
Hip rOAx
Absent 241 16.50 (6.10e40.90) 2.80 (2.76e2.85) 0.713
Present 68 16.35 (8.30e34.20) 2.82 (2.74e2.90)
*rOA deﬁned as KeL grade 2 at the knee or hip.
yFor differences in unadjusted mean lnTGF-b.
zSigniﬁcant in adjusted models containing age, BMI, race, gen-
der; P¼ 0.016 for race and P¼ 0.001 for gender.
































Fig. 1. Adjusted mean lnTGF-b1 by knee rOA severity. The open
box is no rOA, all P values given are compared to no rOA.
773Osteoarthritis and Cartilage Vol. 17, No. 6in the synovial ﬂuid of patients with OA8, and levels after
meniscectomy are reﬂective of future bone and cartilage
changes9. Local administration of TGF-b1 into murine
knee joints induces changes consistent with OA, including
OST formation10, while inhibition of endogenous TGF-
b (all isoforms) decreases OST size and enhances proteo-
glycan loss11. In one of the few studies of TGF-b1 to include
AAs, serum levels among patients with end stage kidney
disease were higher in AAs with compared to Whites, with
no difference by race among healthy controls12. Serum
TGF-b1 has been used as a potential biomarker of OA in
a few studies, with varying results13e15.
We hypothesized that the increased osteophytosis previ-
ously observed in AAs compared to Whites may be associ-
ated with elevated serum TGF-b1 levels in AAs, and with
increased prevalence and/or severity of radiographic osteo-
arthritis (rOA) in these individuals. Therefore, the current
study was designed to test associations of serum TGF-b1
with rOA (both by KeL grade and IRFs) at the hip and
knee among participants in the Johnston County Osteoar-
thritis Project, a community-based cohort of individuals
both with and without OA.
Methods
Baseline data from 330 participants in the Johnston County Osteoarthritis
Project were used in the analysis. Participants for biomarker assessment
were selected to represent approximately equal proportions of AAs, Whites,
women, and men, with and without OA, representing a range of ages, with
complete radiographic data at baseline and a 5-year follow-up visit. Subject
recruitment and overall project design procedures have been described for
the parent study16. In brief, all included participants underwent bilateral
weight-bearing anteroposterior radiography of the knees in extension and su-
pine anteroposterior pelvic radiography. Women under 50 years of age were
not subjected to pelvic radiography and were excluded from analyses of hip
rOA. Radiographs were read without knowledge of participant clinical status
by a single radiologist (JBR) using the KeL radiographic atlas2; inter- and
intra-rater reliability for this reader are high (k¼ 0.86 and 0.89, respec-
tively)17. Knee rOA was deﬁned as a KeL grade 2 in at least one knee,
and laterality as none, unilateral, or bilateral involvement of the knees; hip
rOA was similarly deﬁned. Radiographic severity was deﬁned for knees
and for hips as none for KeL grades of 0 or 1, mild for KeL grade equal
to 2, and moderate/severe for KeL grades of 3 or 4, with the overall grade
for an individual deﬁned by the higher grade for each joint site. Results
were comparable using a 4-level variable with KeL 1 as a separate category,
so the combination of KeL 0 and 1 was deﬁned as ‘‘none’’ in analyses. For
IRFs at the knee, both JSN and OST were evaluated as absent or present in
either knee; severity was deﬁned at the most affected knee according to the
Burnett atlas (0¼ none, 1¼mild, 2,3¼moderate/severe); IRFs at the hip
were similarly deﬁned18.
After collection at the baseline clinic visit, blood and sera were separated
and stored on ice. Sera were frozen within 8 h of collection at 20C, then
transferred for long-term storage to a 86C environment. TGF-b1 was mea-
sured using a sandwich ELISA kit from Biosource International (Camarillo,
CA). This method includes an extraction step to release TGF-b1 from latent
complexes, thus measuring total serum concentrations. Manufacturer re-
ported precision was 5.5e6.2% intra-assay, and 6.6e7.9% inter-assay.
The natural logarithm transformation was used to produce near-normal
distributions for TGF-b1 (lnTGF-b1) in analyses. Descriptive statistics were
calculated for demographic and clinical variables (race, gender, age, and
body mass index (BMI)), knee and hip rOA, and lnTGF-b1; differences
were assessed by two-sample t tests. General linear models were used sep-
arately for knee and hip rOA to obtain adjusted (least squares means) esti-
mates for lnTGF-b1 and rOA presence, laterality, and severity as well as the
presence and severity of IRFs. Models were adjusted for age, gender, self-
reported race, and BMI. Interactions by race and gender were assessed and
considered signiﬁcant at a P value< 0.1. Stratiﬁed analysis was performed
using general linear models to assess differences in IRFs by race. All anal-
yses were performed using SAS version 9.1 (Cary, NC).
Results
The mean age (SD) of the sample (n¼ 330) was
60.5 9.4 years, with a mean BMI of 30.3 6.9 kg/m2;
42% were AA and 39% were men. Fifty-four percent of par-
ticipants had knee rOA and 22% had hip rOA. The overallmedian serum TGF-b1 was 16.75 ng/mL (range
6.1e40.9 ng/mL); mean serum lnTGF-b1 was
2.82 0.34 ng/mL. Mean serum lnTGF-b1 was higher
among AA participants compared to Whites (P¼ 0.009),
and among women compared to men (P¼ 0.001, Table I).
There were no signiﬁcant associations between lnTGF-b1
levels and age or BMI (data not shown). No signiﬁcant dif-
ferences were identiﬁed for mean serum lnTGF-b1 levels
by the presence of rOA status at the knee or the hip in un-
adjusted analyses (Table I).
Compared to those without hip rOA, lnTGF-b1 levels
were higher in those with bilateral hip involvement, but
these differences were not statistically signiﬁcant before
or after adjustment (P> 0.5; data not shown). Small num-
bers in more severe categories precluded meaningful anal-
ysis of hip rOA by severity. There were no associations
between lnTGF-b1 levels and unilateral or bilateral knee
rOA (all P values> 0.3; data not shown). Compared to
those without knee rOA, mean lnTGF-b1 was higher in
moderate/severe knee rOA (P¼ 0.080); this association
was attenuated after adjustment (P¼ 0.188, Fig. 1). There
was no evidence for a linear trend between increasing
lnTGF-b1 and increasing knee rOA severity.
Mean serum lnTGF-b1 levels by IRFs of OA at the knee
and hip are shown in Table II. There were no signiﬁcant
Table II
Unadjusted and adjusted* mean lnTGF-b1 by IRFs of OA
ny Unadjusted 95% CI P valuez Adjusted* 95% CI P valuez
Hip JSN
Absent 226 2.81 2.76e2.85 0.937 2.80 2.78e2.85 0.857
Present 80 2.81 2.74e2.88 2.81 2.74e2.89
Hip OST
Absent 155 2.79 2.74e2.84 0.296 2.80 2.74e2.85 0.608
Present 149 2.83 2.78e2.88 2.82 2.76e2.87
Knee JSN
Absent 140 2.78 2.73e2.84 0.093 2.79 2.73e2.85 0.217
Present 189 2.85 2.80e2.90 2.84 2.79e2.89
Knee OST
Absent 126 2.77 2.71e2.83 0.034 2.78 2.72e2.84 0.136
Present 200 2.85 2.80e2.90 2.84 2.79e2.89
*adjusted for age, BMI, race, and gender.
yn¼ 306 for hip JSN, 304 for hip OST, 329 for knee JSN, and 326 for knee OST.
zP value compared to absent or none.
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of JSN or OST at the hip. There were no associations be-
tween mean lnTGF-b1 and the presence or severity of
JSN at the knee (Fig. 2). Signiﬁcant associations between
increasing lnTGF-b1 levels and knee OST presence and
severity in unadjusted analyses (P¼ 0.034 and 0.030, re-
spectively) were attenuated after adjustment (P¼ 0.136
for both, Table II, Fig. 2).
There were no signiﬁcant interactions between lnTGF-b1
and race or gender for rOA outcomes, either by KeL grade
or IRFs. Nonetheless, stratiﬁed analysis by race was carried
out for IRFs at the knee, given our a priori hypothesis regard-
ing the possibility of racial differences. This analysis again
showed no association between JSN presence or severity
at the knee in AA orWhite individuals (data not shown). How-
ever, there was a borderline signiﬁcant association between
elevated lnTGF-b1 andOST presence among AA individuals
(mean lnTGF-b1 for no OST: 2.77 (95% CI 2.65e2.88), for
OST present: 2.90 (2.83e2.97), P¼ 0.056 after adjustment
for age, gender, and BMI) that was not seen among Whites
(no OST mean lnTGF-b1: 2.76 (2.69e2.83), OST present:
2.79 (2.72e2.86), P¼ 0.613). Similarly for OST severity at































Fig. 2. Adjusted mean lnTGF-b1 by knee JSN and OST. The left side of t
referent; P values are compared to no JSN. The right side of the ﬁgure sh
values are compareamong AAs for increasing lnTGF-b1 levels with mild and
moderate/severe OST, compared to none (Fig. 3); there
was no association between OST severity and lnTGF-b1
levels among Whites.
Discussion
In our population of AA and White individuals with and
without hip and knee rOA, serum TGF-b1 levels did not dif-
ferentiate OA from non-OA states, and did not vary signiﬁ-
cantly by severity or unilateral vs bilateral involvement.
After adjustment for age, BMI, gender, and race, there
were no associations between serum TGF-b1 levels and
JSN or OST at the knee or the hip. Despite higher serum
TGF-b1 levels among AAs and women, no race or gender
interactions were seen for OA outcomes, indicating no dif-
ferences in the association of TGF-b1 levels and OA in
these subgroups. However, there was a suggestion of an
association between OST and lnTGF-b1 among AAs only,
in a stratiﬁed analysis.
Our results are in agreement with a prior study by Otter-
ness et al., who found that serum TGF-b1 did not discrimi-
nate between subjects with and without hip or knee OANone Mild Mod/severe
p=0.205 p=0.136
OST
he ﬁgure shows mean lnTGF-b1 by Knee JSN, with no JSN as the
ows mean lnTGF-b1 by Knee OST, with no OST as the referent; P




































Fig. 3. Adjusted mean lnTGF-b1 by OST severity, stratiﬁed by race. The left side of the ﬁgure shows mean lnTGF-b1 by Knee OST among
African Americans, while the right side of the ﬁgure shows lnTGF-b1 by Knee OST among Whites. No OST is the referent, all P values are
compared to no OST.
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graphic criteria13. A study of the same biomarkers using
clinical outcomes identiﬁed only a borderline signiﬁcant cor-
relation between serum TGF-b1 and change in clinical sta-
tus over a year, a category including such variables as
physician and patient assessments of change in disease
status, and changes in stiffness and pain. The number of
subjects in the study was small (n¼ 39), as was the r2 for
the identiﬁed correlation (r2¼ 0.17, P¼ 0.05)14. A larger
study (n¼ 193) in a cohort undergoing a diet and exercise
intervention15 found a negative correlation between base-
line serum TGF-b1 and baseline KeL grade at the knee
(r¼0.19, P¼ 0.01), but no association with follow-up out-
comes including clinical, functional, or radiographic mea-
sures, or with change in the biomarker level and change
in outcome measures over 18 months15.
There are several limitations to the use of systemic bio-
markers in OA, including often incomplete assessment of
potential confounders (race, gender, medical comorbidities)
and the effect of joint sites other than those under study. In
the current study, we had radiographic information only for
the hip and the knee, and we had a small sample size for
more severe outcome levels. Finally, we focused on a single
marker at a single time point and so cannot speciﬁcally
comment on the potential of TGF-b1 as a marker of pro-
gression. Baseline TGF-b as a predictor of incident or pro-
gressive knee rOA will be the subject of future study.
This study has signiﬁcant strengths. It is the largest study
of TGF-b1 in OA to date and includes AA and White men
and women and radiographic data from two large joint sites.
We identiﬁed higher levels of TGF-b1 in AAs and women.
Despite the relatively large size of our sample, given the
lack of apparent independent signiﬁcant associations be-
tween serum TGF-b1 and rOA presence, severity, or later-
ality, or JSN or OST, it seems unlikely that this biomarker
will be useful as a stand-alone biomarker in future OA stud-
ies. However, the potential importance of TGF-b1 among
AA individuals warrants further investigation.
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